Novo Nordisk Lifts 2026 Outlook on Strong Q2 Sales and Profit

summarizeSummary

Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to 0% to -6% at CER, up from -4% to -12%, after Q2 adjusted sales grew 7% and adjusted operating profit grew 11%, driven by GLP-1 products.

check_boxKey Events · Earnings and Guidance · NVO

• 2026 Outlook Raised

  Full-year adjusted sales growth is now seen at 0% to -6% at CER, up from -4% to -12%; adjusted operating profit growth was also raised to 0% to -6% from -4% to -12%.

• Q2 Sales and Profit Growth

  Q2 2026 adjusted sales increased 7% at CER to DKK 78.5 billion, and adjusted operating profit increased 11% at CER to DKK 33.4 billion, excluding 340B provision reversals.

• Non-Cash Impairment Charges

  Q2 2026 included DKK 6.3 billion in non-recurring, non-cash impairment charges, primarily DKK 4.0 billion for monlunabant, which reduced reported profit but did not affect adjusted figures.

• GLP-1 Demand Drives Upgrade

  The improved outlook is attributed to increased expectations for GLP-1 product sales, indicating sustained demand for Wegovy and Ozempic despite competitive pressures.

auto_awesomeAnalysis · NVO · Life Sciences

Driven by robust GLP-1 product sales, Novo Nordisk raised its full-year 2026 adjusted sales and operating profit guidance to 0% to -6% at constant exchange rates, up from -4% to -12% previously. Q2 adjusted sales rose 7% and adjusted operating profit rose 11%, both at CER, despite a DKK 6.3 billion non-cash impairment charge, including DKK 4.0 billion for monlunabant. The upgrade reverses a downward trend and signals that demand for its obesity and diabetes franchise remains resilient, even as the company navigates pipeline setbacks like the recent ZEUS trial failure.